Yemen
Support for Vaccine: Pentavalent
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Yemen


3. **Date of Decision Letter:** 11-Jul-19

4. **Date of the Partnership Framework Agreement:** Not applicable

5. **Programme title:** New Vaccine Support (NVS), Pentavalent, Routine

6. **Vaccine type:** Pentavalent

7. **Requested product presentation and formulation of vaccine:** Pentavalent, 1 dose(s) per vial, LIQUID

8. **Programme Duration:** 2007-2019

9. **Programme Budget (indicative):**

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2007-2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>57,267,797</td>
<td>2,684,500</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>59,952,297</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant**
    Not applicable

11. **Product switch grant**
    Not applicable

12. **Indicative Annual Amounts:**

    | Type of supplies to be purchased with Gavi funds | 2007-2018 | 2019 | 2020 |
    |-----------------------------------------------|----------|------|------|
    | Number of vaccine doses                        |          | 2,395,300 | -    |
    | Annual Amounts (US$)                           | 57,267,797 | 2,684,500 | -    |

13. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. **Self-procurement:** Not applicable

15. **Co-financing obligations:**
    According to the co-financing policy, the Country falls within the group: Preparatory transition phase

---

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the total amount approved by Gavi.
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>423,200</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>443,300</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>4,900</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>444,296</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total co-financing payments (US$ (including freight)</td>
<td>494,500</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

16. Operational support for catch-up campaigns:

Not applicable

17. Additional Reporting Requirements:

To prepare for the annual procurement of vaccines, Country shall submit the following information each year:
- vaccine stock levels including buffer stock, by end of March;
- number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.
- Countries shall report the actual switch date in the first renewal request following the actual implementation.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

| Periodicity and dates to be agreed with Gavi Secretariat |

18. Financial clarifications: Country shall provide the following clarifications to Gavi*:

Not applicable

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

19. Other conditions: Not applicable

On behalf of Gavi

Pascal Bijleveld
Managing Director, Country Programmes a.i.